- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04690842
Improving Safety in Pediatric Thyroidectomy by PTH Measurements
Implementation of PTH Measurement Intra / Post Thyroidectomy to Improve Post Surgical Safety in Pediatric Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Sixty-six patients were included in the analysis. Based on their intra-operatory PTH determinations, patients were classified according to their post-surgical hypoparathyroidism risk and were either immediately treated with calcium and vitamin D1-25 supplementation (high-risk) or assigned to clinical control and routine calcium sampling (low-risk). The outcomes and overall results of these therapeutical approaches were compared with those of a control group, started on treatment when TCa levels dropped below normal.
In the high-risk subgroup (n=30) five patients showed hypocalcemia within the first 24 hours. Compared with the high-risk control subgroup, the incidence of hypocalcemia fell from 100% to 17% (p<0.001), and the median hospitalization length from 6 to 3 days (p<0.001).
In the low-risk subgroup (n=36) 28 patients remained normocalcemic with significantly less calcium sampling (p<0.001). Eight patients had hypocalcemia; 7 of them required neck dissection, which was the only risk factor related to post-surgical hypoparathyroidism (RR: 2.1 [CI 95% 1.4-3.1], P<0.001).
Compared to the control group, overall incidence of hypocalcemia was reduced by 58 %.
This approach improved patient's safety by reducing the occurrence of hypocalcemia and the length of hospitalization after thyroidectomy in pediatric patients. Preventive calcium supplementation seems to be more beneficial in patients undergoing neck dissection.
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients who underwent total thyroidectomy between January 2014 and April 2020
Exclusion Criteria:
- Patients with known hyper or hypoparathyroidism, kidney failure, and those taking medications known to affect TCa, PTH, or vitamin D levels (octreotide, oral glucocorticoids, diuretics and antiepileptics), or any other condition that could interfere with calcium metabolism
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biochemical hypocalcemia post thyroidectomy occurrence
Time Frame: 48 hours postthyroidectomy
|
total Calcium level < 8 mg/dl
|
48 hours postthyroidectomy
|
Symptomatic hypocalcemia post thyroidectomy ocurrence
Time Frame: 48 hours posthyroidectomy
|
Signs o symptoms of hypocalcemia (Chvostek or Trousseau signs, tingling, numbness, muscle cramps, spasms, tetany or seizures
|
48 hours posthyroidectomy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
days of hospitalization after thyroidectomy
Time Frame: up to 15 days after thyroidectomy
|
number of days that patient need hospitalization (high risk group)
|
up to 15 days after thyroidectomy
|
number of Calcium sampling
Time Frame: 48 hours postthyroidectomy
|
number of venipuncture performed to control serum calcium level (low risk group)
|
48 hours postthyroidectomy
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CEI 19.27
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypoparathyroidism Postprocedural
-
Odense University HospitalActive, not recruitingHypoparathyroidism PostproceduralDenmark
-
Nantes University HospitalFondation SantéDige; Association Francophone de Chirurgie Endocrinienne (AFCE)RecruitingHypoparathyroidism Postprocedural | ThyroidectomyFrance
-
University of AthensCompletedHypoparathyroidism PostproceduralGreece
-
Region SkaneJagiellonian University; Sahlgrenska University Hospital, Sweden; Haukeland University... and other collaboratorsCompletedHypoparathyroidism PostproceduralNorway, Sweden, Austria, Poland
-
CHU de Quebec-Universite LavalRecruitingQuality of Life | Hypoparathyroidism PostproceduralCanada
-
Fundación de Investigación Biomédica - Hospital...CompletedHypoparathyroidism PostproceduralSpain
-
University of Roma La SapienzaCompletedEvaluation of iMmune Function in Post-surgical and AuToimmune HYpoparathyroidism (EMPATHY) (EMPATHY)Hypoparathyroidism | Hypoparathyroidism Postprocedural | Hypoparathyroidism Due to Impaired Parathormone SecretionItaly
-
Rigshospitalet, DenmarkCluster for molecular imaging, Denmark; Dept of Otorhinolaryngology and Maxillofacial...RecruitingSurgery--Complications | Hypocalcemia | Hypoparathyroidism PostproceduralDenmark
-
Hospital Son EspasesUniversitat de les Illes BalearsUnknownHypocalcemia | Hypoparathyroidism Postprocedural | Total ThyroidectomySpain
-
Onze Lieve Vrouw HospitalRecruitingHypoparathyroidism Postprocedural | Thyroid DiseaseBelgium